ArticleClinical and experimental medicine2026
Global trends in the burden of inflammatory bowel disease from 1990 to 2021: socioeconomic and sex-specific disparities with exploratory mendelian randomization analyses.
Article in Clinical and experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Inflammatory bowel disease (IBD) shows substantial variation in burden across regions and populations worldwide. However, patterns of IBD b3urden across levels of socio-demographic development remain incompletely characterized, and complementary evidence on selected individual-level exposures is limited. Utilizing GBD 2021 data, we assessed age-standardized incidence rate (ASIR), prevalence rate (ASPR), mortality rate (ASMR), and disability-adjusted life years rate (ASDR) from 1990 to 2021 across socio-demographic index (SDI) strata. Temporal trends were estimated using estimated annual percentage change and Joinpoint regression. Pearson analysis and frontier analyses assessed SDI correlations, while inequality was measured using the concentration index and slope index. Decomposition analysis was performed to identify the contributors of population growth, population aging, and epidemiological change. Two-sample Mendelian randomization (MR) analysis was conducted to examine potential associations between selected exposures and IBD. From 1990 to 2021, the global ASIR rose by 0.29 annually, while ASPR, ASMR and ASDR decreased by 0.13, 0.31 and 0.52. Burden patterns differed across SDI strata. High SDI regions had the highest age-standardized burden in 2021. The largest increases in ASIR and ASPR were observed in middle SDI regions, and declines in ASMR and ASPR began later in low SDI regions than in high SDI regions. ASDR was positively correlated with SDI in females but not in males, and cross-country inequality in ASDR was greater in females than in males. Decomposition analysis showed that population aging contributed more to changes in ASMR and ASDR in high SDI regions, while population growth was the dominant contributor in low SDI regions. Fifteen countries showed large effective differences between observed ASDR and frontier values at comparable SDI levels. In MR analyses, several nominal associations were observed, but none remained significant after false discovery rate (FDR) correction. The burden of IBD showed substantial heterogeneity across SDI levels and between sexes in GBD 2021, with a more pronounced inequality pattern in disability burden among women. The MR findings did not remain significant after FDR correction and should therefore be interpreted cautiously as exploratory signals. These findings underscore the importance of context-specific strategies to reduce inequalities in IBD burden across populations and between women and men.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.